TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Improving Holding Function of the Hemiplegic Hand

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who are clinically appropriate for treatment of upper limb spasticity due to stroke with Botox A injections ;~* adults up to age 80, women must be post-menopausal or are medically unable to conceive (as determined from their medical records), men must be at least age 35~* documented anemic or hemorrhagic unilateral (right or left) hemiplegic stroke, with 1 year or more prior to enrollment~* able to understand verbal and visual instructions and demonstrations regarding the protocol~* a resting wrist angle equal to or less than 0~* spasticity is present in finger flexors and thumb coupled with marked voluntary paresis of finger extension (no finger has more than half range of active extension at any joint). By squeezing the examiner's finger, participants will have demonstrated, at least, some detectable voluntary contraction of finger flexors; impaired sensation is acceptable but participants must be aware that they are holding something, as tested clinically;~* at least two finger flexors with an Ashworth score = 3;~* moderate motor severity as defined by an upper limb Fugl-Meyer motor scores between 21-50~* normal joint capsule without contractures as determined by clinical exam; participant may have tightness/shortening of extrinsic finger flexors but composite extension of wrist and fingers comes to at least neutral (i.e. fingers and wrist can be brought to neutral position simultaneously).~Exclusion Criteria:~* profound sensory loss/absent touch sensation~* known hypersensitivity/allergy to Botox A~* acute illness or unresolved medical/psychiatric conditions at time of assessment~* symptomatic lung disease and compromised respiratory status; muscle-weakening neurological disorders known to increase drug-related risk \[e.g. amyotrophic lateral sclerosis (ALS), myasthenia gravis, Lambert-Eaton syndrome, or motor neuropathy\]~* infection in the area where the study drug should be injected~* pregnancy or breast-feeding;~* participant had Botox injections less than 4 months previously~* clenched fist associated with tenodesis of an extended wrist i.e. resting position of wrist is \> 0 degrees

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- clenched fist (Type: None): Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a boy or a girl 2 months ± one week old at the time of the first dose of the vaccine.~* The subject is considered to be healthy based on the clinical history and the physical examination.~* The subject has not received any anti-rotavirus vaccine.~* The parent/tutor fully understands the study's procedures and voluntarily accepts to participate and signs a written informed consent.~* The parent/tutor can meet the study's requirements, such as attending the programmed visits and filling in the journal.~* Written informed consent signed by the parent/tutor before any procedure.~Exclusion Criteria:~* The subject has a background of serious allergic reaction to any of the vaccine's components.~* The subject has a digestive tract malformation or acute/chronic disease.~* The subject has some kind of immunodeficiency including HIV.~* The subject suffers from a haemato-oncological disease.~* The subject has been under treatment with an immunosuppressing medicine including prednisone for two or more weeks.~* The subject has received gamma-globulin or any other blood-derived product or its administration is programmed during the study.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Study Arms:
- ROTA 1 (Type: ACTIVE_COMPARATOR): two doses of monovalent vaccine Rotarix followed by one dose of sterile water
- ROTA 2 (Type: ACTIVE_COMPARATOR): three doses of pentavalent vaccine RotaTeq
- ROTA 3 (Type: ACTIVE_COMPARATOR): one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
- ROTA 4 (Type: ACTIVE_COMPARATOR): one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
- ROTA 5 (Type: ACTIVE_COMPARATOR): two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
- ROTA 6 (Type: ACTIVE_COMPARATOR): one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
- ROTA 7 (Type: ACTIVE_COMPARATOR): a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a urogenital gonococcal infection (prior culture, NAAT test, Gram stain, sexual contact)~2. Willing to abstain from anal, oral, or vaginal sexual intercourse or use condoms until study completion.~3. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrollment.~Exclusion Criteria:~1. Confirmed, or suspected, complicated or systemic gonococcal infections such as pelvic inflammatory disease, arthritis, or endocarditis.~2. Known HIV, chronic hepatitis B, or hepatitis C infection.~3. Known concomitant infection which would require additional systemic antibiotics.~4. Use of systemic or intravaginal antibiotics within 30 days prior to study drug administration.~5. Current use of corticosteroid drugs or other immunosuppressive therapy.~6. Cytotoxic chemotherapy or radiation therapy within the previous 3 months.~7. Known significant renal, hepatic, or hematologic impairment.~8. History of intolerance or hypersensitivity to macrolide antibiotics.~9. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g., life expectancy \<30 days).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solithromycin (CEM-101) (Type: EXPERIMENTAL): A single oral dose of 1200 mg solithromycin
- Solithromycin 1000 mg (Type: EXPERIMENTAL): A single oral dose of 1000 mg solithromycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD465 in Adults With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of ADHD using DSM-IV-TR criteria (at least 6 of the 9 subtype criteria met)~* Baseline ADHD-RS-IV score =\>24~* IQ score of =\> 80 (using Kaufman Brief Intelligence Test)~Exclusion Criteria:~* BMI \< 18.5 or \> 30 kg/m2~* Diagnosis of Post Traumatic Stress Disorder, psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder~* History of seizure disorder or a lifetime history of any seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder~* History of uncontrolled hypertension or currently hypertensive~* Subjects who have taken atomoxetine (STRATTERA) within 30 days prior to screening~* Current (or history within the last 12 months) of drug dependence or substance abuse disorder according to DSM-IV-TR criteria (excluding nicotine)~* Female subject is pregnant or lactating, less than 3 months post partum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Between DWJ1421 and DWC201903 in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 19 aged and 45 aged in healthy male adult~* Body weight more than 50kg~* Body Mass Index more than 18.0 and under 27.0~Exclusion Criteria:~* Those who have clinical significant liver, kidney, digestive system, respiratory, endocrine, nervous system, hematology and oncology, cardiovascular, urinary diseae or past history~* Those who have a gastrointestinal disease history that can effect drug absorption or surgery~* Those who have hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of Investigational product

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A (RT) (Type: EXPERIMENTAL): Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
- B (TR) (Type: EXPERIMENTAL): Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed non-clear cell renal cell carcinoma (papillary, chromophobe, collecting duct, oncocytic subtype, sarcomatoid mainly)~2. Subjects with metastatic legion~3. Subjects aged 18 years or older~4. Subjects whose ECOG performance status is 0 or 1~5. Subjects who have laboratory value below; Hematology~   * Neutrophil \>= 1.5 x 109/L~  * Platelet \>= 75 x 109/L~  * Hemoglobin \>= 9 g/dL Liver function tests~  * Total bilirubin ≤ 1.5 xULN~  * AST, ALT ≤ 2.5 xULN~  * Alkaline phosphatase ≤ 2.5 xULN Renal function tests~  * Creatinine clearance \>= 30 mL/min~6. Subjects who understand and provide a written informed consent~Exclusion Criteria:~1. Subjects who have been administered an mTOR inhibitor~2. Pregnant or nursing women, and women of childbearing potential must use appropriate contraception for the study period and the result of their pregnancy test performed within 14 days before enrollment must be negative~3. Subjects who participated in a clinical study using the study medication within 30 days before randomization~4. Subjects with clinically uncontrolled central nervous system (CNS) metastasis~5. Subjects with life expectancy of less than 3 months~6. Subjects with interstitial pulmonary disease~7. Subjects whose QTc interval is prolonged (QTc \> 450 msec for male or \> 470 msec for female)~8. Other serious diseases or medical conditions Heart disease unstable despite treatment History of myocardial infarction within six months before the study History of serious neurological or psychological disorder including dementia or seizure Active peptic ulcer which cannot be controlled by a drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 (Type: EXPERIMENTAL): RAD001 10mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 30-80~2. Parkinson disease~3. On dopamine agonists (Ropinirole IR or Pramipexole IR) and are considering to change into Ropinirole PR~4. On stable antiparkinsonian medication for at least 4 weeks~5. Who signed consent to the study~Exclusion Criteria:~1. Who are on less than 2 mg of Ropinirole IR or 0.375 mg of Pramipexole IR~2. Who have dementia, psychosis, major depression and other serious neurological or medical problems~3. Who are allergic to the similar medications~4. Who has history of heavy metal poisoning~5. Who were on othe clinical trials of other medications within the last 4 weeks~6. Whoa re pregnant or lactating~7. Who are considered not eligible by the investigator

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ropinirole PR QD first, then BID (Type: ACTIVE_COMPARATOR): Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
- Ropinirole PR BID first, and then QD (Type: ACTIVE_COMPARATOR): Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy and non-sedentary men aged 50-70 years~Exclusion Criteria:~* pituitary disease, GH use in the last 12 months, severe acute disease, hepatic and/or renal chronic disease, uncontrolled systemic arterial hypertension, diabetes mellitus, psychiatric disorders, history of cancer, non-treated hypogonadism and the presence of any other disease that could interfere with the somatotrophic axis.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- growth hormone (Type: EXPERIMENTAL): GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients are in- and outpatients, having a primary diagnosis of severe major depressive disorder (SCID-I diagnosis in agreement with DSM-5 criteria and a Hamilton Rating Scale for Depression score ≥ 19 (HAM-D-17-item version), aged 18-65 years, who, according to their physician, are eligible for treatment with a TCA (Nortriptyline (NOR), Clomipramine (CLOMI) or Imipramine (IMI)). The choice of the specific TCA is at the discretion of the physician in attendance.~Exclusion Criteria:~1. Psychotic depression~2. Bipolar I or II disorder.~3. Schizophrenia or other primary psychotic disorder.~4. Drug or alcohol dependence in the past 3 months.~5. Mental Retardation (IQ \< 80).~6. For women: pregnancy or possibility for pregnancy without adequate contraceptive measures.~7. Breastfeeding.~8. Serious medical illness affecting the CNS, including but not restricted to M Parkinson, SLE, brain tumour, CVA.~9. Relevant medical illness as contra-indication for TCA use, such as recent myocardial infarction.~10. Other drugs influencing the pharmacokinetics of the TCAs as based on a list of interacting drugs. In case of psychotropic co-medication only a benzodiazepine in a dose equivalent up to 4 mg lorazepam will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Genotype-guided TCA treatment (Type: EXPERIMENTAL): Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
- Standard TCA treatment (Type: ACTIVE_COMPARATOR): Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and dating the informed consent form.~2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to 38 days from the start of 1 menstrual period until the start of the next, by participant history for at least 3 months prior to the first screening visit.~3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or transabdominal ultrasound performed during the screening period.~4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as measured by the alkaline hematin method during the screening period.~Key Exclusion Criteria:~1. Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the patient's heavy menstrual bleeding.~2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.~3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine and proximal femur.~4. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the participant's bone mineral density is within normal limits.~5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss.~6. Has been a participant in an investigational drug or device study within the 1 month prior to the first screening visit.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Group A) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 24 weeks.
- Relugolix plus Delayed E2/NETA (Group B) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
- Placebo (Group C) (Type: PLACEBO_COMPARATOR): Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete